2025

Reply to: "Optimising the treatment of HDV infection: Efficacy of bulevirtide, HBV-HDV interactions and the importance of statistical methods"
Dandri M, Allweiss L, Downie B, Wallin J
J HEPATOL. 2025;82(2):e109.

Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg-IFNα-2a as Treatment for Chronic Hepatitis Delta
Lampertico P, Bogomolov P, Chulanov V, Stepanova T, Morozov V, Allweiss L, Dandri M, Burhenne J, Blank A, Ciesek S, Elsner C, Dittmer U, An Q, Manuilov D, Da B, Flaherty J, Urban S, Wedemeyer H
LIVER INT. 2025;45(2):e70008.

2024

Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies
Allweiss L, Volmari A, Suri V, Wallin J, Flaherty J, Manuilov D, Downie B, Lütgehetmann M, Bockmann J, Urban S, Wedemeyer H, Dandri M
J HEPATOL. 2024;80(6):882-891.

SMC5/6-Mediated Transcriptional Regulation of Hepatitis B Virus and Its Therapeutic Potential
Bächer J, Allweiss L, Dandri M
VIRUSES-BASEL. 2024;16(11):1667.

Multiscale modeling of HBV infection integrating intra- and intercellular viral propagation to analyze extracellular viral markers
Kitagawa K, Kim K, Iwamoto M, Hayashi S, Park H, Nishiyama T, Nakamura N, Fujita Y, Nakaoka S, Aihara K, Perelson A, Allweiss L, Dandri M, Watashi K, Tanaka Y, Iwami S
PLOS COMPUT BIOL. 2024;20(3):.

Availability of point-of-care HBV tests in resource-limited settings
Lau D, Jackson K, Picchio C, Kramvis A, Sonderup M, Lemoine M, Matthews G, Howell J, Coffin C, Hellard M, Lee A, Anderson D, Kerth H, Lee E, Travis J, Dandri-Petersen M, Revill P, Spearman C, Penicaud M, Levrero M, El-Sayed M
LANCET GASTROENTEROL. 2024;9(12):1073-1076.

Method for Quantitative HDV RNA Detection: I, Manual Workflow (Serum and Liver Tissue) and II, Fully Automated High Throughput Workflow for Diagnostic Use
Pflüger L, Volz T, Giersch K, Allweiss L, Dandri-Petersen M, Lütgehetmann M
2024. Hepatitis B Virus. Guo H, Cuconati A (Hrsg.). 1. Aufl. New York: Humana Press, 171-184.

Rapid and Reliable Protein-Free HBV DNA Extraction and Sensitive Branched DNA Southern Blot Assay
Yu M, Dandri M, Cheng G, Delaney W, Fletcher S, Allweiss L
2024. Hepatitis B Virus. Guo H, Cuconati A (Hrsg.). 1. Aufl. New York: Humana Press, 113-124.

Hepatitis B Virus DNA integration: Implications for diagnostics, therapy, and outcome
Zoulim F, Chen P, Dandri-Petersen M, Kennedy P, Seeger C
J HEPATOL. 2024;81(6):1087-1099.

2023

Quantification of the hepatitis B virus cccDNA: evidence-based guidelines for monitoring the key obstacle of HBV cure
Allweiss L, Testoni B, Yu M, Lucifora J, Ko C, Qu B, Lütgehetmann M, Guo H, Urban S, Fletcher S, Protzer U, Levrero M, Zoulim F, Dandri-Petersen M
GUT. 2023;72(5):972-983.

Strain-specific responsiveness of hepatitis D virus to interferon-alpha treatment
Giersch K, Perez-Gonzalez P, Hendricks L, Goldmann N, Kolbe J, Hermanussen L, Bockmann J, Volz T, Volmari A, Allweiss L, Petersen J, Glebe D, Lütgehetmann M, Dandri M
JHEP REP. 2023;5(4):100673.

Non-organ-specific autoantibodies with unspecific patterns are a frequent para-infectious feature of chronic hepatitis D
Hermanussen L, Lampalzer S, Bockmann J, Ziegler A, Piecha F, Dandri M, Pischke S, Haag F, Lohse A, Lütgehetmann M, Weiler-Normann C, Zur Wiesch J
FRONT MED-LAUSANNE. 2023;10:1169096.

Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice
Lempp F, Volz T, Cameroni E, Benigni F, Zhou J, Rosen L, Noack J, Zatta F, Kaiser H, Bianchi S, Lombardo G, Jaconi S, Vincenzetti L, Imam H, Soriaga L, Passini N, Belnap D, Schulze A, Lütgehetmann M, Telenti A, Cathcart A, Snell G, Purcell L, Hebner C, Urban S, Dandri M, Corti D, Schmid M
J HEPATOL. 2023;79(5):1129-1138.

Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial
Wedemeyer H, Schöneweis K, Bogomolov P, Blank A, Voronkova N, Stepanova T, Sagalova O, Chulanov V, Osipenko M, Morozov V, Geyvandova N, Sleptsova S, Bakulin I, Khaertynova I, Rusanova M, Pathil A, Merle U, Bremer B, Allweiss L, Lempp F, Port K, Haag M, Schwab M, Zur Wiesch J, Cornberg M, Haefeli W, Dandri M, Alexandrov A, Urban S
LANCET INFECT DIS. 2023;23(1):117-129.

2022

Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo
Allweiss L, Giersch K, Pirosu A, Volz T, Muench R, Beran R, Urban S, Javanbakht H, Fletcher S, Lütgehetmann M, Dandri-Petersen M
GUT. 2022;71(2):372-381.

The hepatitis delta virus and chronic hepatitis D
Dandri M, Volmari A, Lütgehetmann M
J HEPATOL. 2022;77(5):1448-1450.

A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook
Kramvis A, Chang K, Dandri M, Farci P, Glebe D, Hu J, Janssen H, Lau D, Penicaud C, Pollicino T, Testoni B, Van Bömmel F, Andrisani O, Beumont-Mauviel M, Block T, Chan H, Cloherty G, Delaney W, Geretti A, Gehring A, Jackson K, Lenz O, Maini M, Miller V, Protzer U, Yang J, Yuen M, Zoulim F, Revill P
NAT REV GASTRO HEPAT. 2022;19(11):727-745.

2021

High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities
Bockmann J, Kohsar M, Murray J, Hamed V, Dandri-Petersen M, Lüth S, Lohse A, Schulze-Zur-Wiesch J
MICROORGANISMS. 2021;9(5):.

Innate immunity in hepatitis B and D virus infection: consequences for viral persistence, inflammation, and T cell recognition
Dandri M, Bertoletti A, Lütgehetmann M
SEMIN IMMUNOPATHOL. 2021;43(4):535-548.

In Vivo Models of HDV Infection: Is Humanizing NTCP Enough?
Giersch K, Dandri M
VIRUSES-BASEL. 2021;13(4):588.

Murine hepatocytes do not support persistence of Hepatitis D Virus mono-infection in vivo
Giersch K, Hermanussen L, Volz T, Kah J, Allweiss L, Casey J, Sureau C, Dandri M, Lütgehetmann M
LIVER INT. 2021;41(2):410-419.

Strong Replication Interference Between Hepatitis Delta Viruses in Human Liver Chimeric Mice
Giersch K, Hermanussen L, Volz T, Volmari A, Allweiss L, Sureau C, Casey J, Huang J, Fischer N, Lütgehetmann M, Dandri M
FRONT MICROBIOL. 2021;12:671466.

Clinical establishment of a laboratory developed quantitative HDV PCR assay on the cobas6800 high-throughput system
Pflüger L, Nörz D, Volz T, Giersch K, Giese A, Goldmann N, Glebe D, Bockmann J, Pfefferle S, Dandri M, Schulze Zur Wiesch J, Lütgehetmann M
JHEP REP. 2021;3(6):.

Chromatin Extraction from Frozen Chimeric Liver Tissue for Chromatin Immunoprecipitation Analysis
Pirosu A, Allweiss L, Dandri-Petersen M
JOVE-J VIS EXP. 2021;2021(169):.

2020

High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection:longitudinal analysis of a German cohort:longitudinal analysis of a German cohort
Bockmann J, Grube M, Hamed V, von Felden J, Landahl J, Wehmeyer M, Giersch K, Hall M, Murray J, Dandri M, Lüth S, Lohse A, Lütgehetmann M, Schulze Zur Wiesch J
BMC GASTROENTEROL. 2020;20(1):24.

Epigenetic modulation in chronic hepatitis B virus infection
Dandri M
SEMIN IMMUNOPATHOL. 2020;42(2):173-185.

cccDNA Maintenance in Chronic Hepatitis B - Targeting the Matrix of Viral Replication
Dandri M, Petersen J
INFECT DRUG RESIST. 2020;13:3873-3886.

Neuropathology of patients with COVID-19 in Germany: a post-mortem case series
Matschke J, Lütgehetmann M, Hagel C, Sperhake J, Schröder A, Edler C, Mushumba H, Fitzek A, Allweiss L, Dandri M, Dottermusch M, Heinemann A, Pfefferle S, Schwabenland M, Sumner Magruder D, Bonn S, Prinz M, Gerloff C, Püschel K, Krasemann S, Aepfelbacher M, Glatzel M
LANCET NEUROL. 2020;19(11):919-929.

Hepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hepatitis B Virus-Infected Hepatocytes
Tham C, Kah J, Tan A, Volz T, Chia A, Giersch K, Ladiges Y, Loglio A, Borghi M, Sureau C, Lampertico P, Lütgehetmann M, Dandri-Petersen M, Bertoletti A
CELL REP MED. 2020;1(4):100060.

A novel method to precisely quantify hepatitis B virus covalently closed circular (ccc)DNA formation and maintenance
Tu T, Zehnder B, Qu B, Ni Y, Main N, Allweiss L, Dandri M, Shackel N, George J, Urban S
ANTIVIR RES. 2020;181:104865.

Hepatitis B Virus Particles Activate Toll-Like Receptor 2 Signaling Initially Upon Infection of Primary Human Hepatocytes
Zhang Z, Trippler M, Real C, Werner M, Luo X, Schefczyk S, Kemper T, Anastasiou O, Ladiges Y, Treckmann J, Paul A, Baba H, Allweiss L, Dandri M, Gerken G, Wedemeyer H, Schlaak J, Lu M, Broering R
HEPATOLOGY. 2020;72(3):829-844.

2019

A global scientific strategy to cure hepatitis B

LANCET GASTROENTEROL. 2019;4(7):545-558.

Comparative Analysis of the Antiviral Effects Mediated by Type I and III Interferons in Hepatitis B Virus-Infected Hepatocytes
Bockmann J, Stadler D, Xia Y, Ko C, Wettengel J, Schulze Zur Wiesch J, Dandri M, Protzer U
J INFECT DIS. 2019;220(4):567-577.

Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo
Giersch K, Bhadra O, Volz T, Allweiss L, Riecken K, Fehse B, Lohse A, Petersen J, Sureau C, Urban S, Dandri M, Lütgehetmann M
GUT. 2019;68(1):150-157.

CD49a Expression Identifies a Subset of Intrahepatic Macrophages in Humans
Martrus G, Goebels H, Langeneckert A, Kah J, Flomm F, Ziegler A, Niehrs A, Löbl S, Russu K, Hess L, Salzberger W, Poch T, Nashan B, Schramm C, Oldhafer K, Dandri M, Koch M, Lunemann S, Altfeld M
FRONT IMMUNOL. 2019;10:1247.

T cell receptor grafting allows virological control of Hepatitis B virus infection
Wisskirchen K, Kah J, Malo A, Asen T, Volz T, Allweiss L, Wettengel J, Lütgehetmann M, Urban S, Bauer T, Dandri M, Protzer U
J CLIN INVEST. 2019;129(7):2932-2945.

Down-regulation of cell membrane localized NTCP expression in proliferating hepatocytes prevents hepatitis B virus infection
Yan Y, Allweiss L, Yang D, Kang J, Wang J, Qian X, Zhang T, Liu H, Wang L, Liu S, Sui J, Chen X, Dandri M, Zhao J, Lu F
EMERG MICROBES INFEC. 2019;8(1):879-894.

2018

Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo
Allweiss L, Volz T, Giersch K, Kah J, Raffa G, Petersen J, Lohse A, Beninati C, Pollicino T, Urban S, Lütgehetmann M, Dandri M
GUT. 2018;67(3):542-552.

Efficacy of NVR 3-778, Alone and in Combination With Pegylated Interferon, vs Entecavir in uPA/SCID Mice With Humanized Livers and HBV Infection
Klumpp K, Shimada T, Allweiss L, Volz T, Lütgehetmann M, Hartman G, Flores O, Lam A, Dandri-Petersen M
GASTROENTEROLOGY. 2018;154(3):652-662.e8.

Nonlytic Lymphocytes Engineered to Express Virus-Specific T-Cell Receptors Limit HBV Infection by Activating APOBEC3
Koh S, Kah J, Tham C, Yang N, Ceccarello E, Chia A, Chen M, Khakpoor A, Pavesi A, Tan A, Dandri M, Bertoletti A
GASTROENTEROLOGY. 2018;155(1):180-193.e6.

Interactions Between KIR3DS1 and HLA-F Activate Natural Killer Cells to Control HCV Replication in Cell Culture
Lunemann S, Schöbel A, Kah J, Fittje P, Hölzemer A, Langeneckert A, Hess L, Poch T, Martrus G, Garcia-Beltran W, Körner C, Ziegler A, Richert L, Oldhafer K, Schulze Zur Wiesch J, Schramm C, Dandri M, Herker E, Altfeld M
GASTROENTEROLOGY. 2018;155(5):1366-1371.

A Novel Orally Available Small Molecule That Inhibits Hepatitis B Virus Expression
Mueller H, Wildum S, Luangsay S, Walther J, Lopez A, Tropberger P, Ottaviani G, Lu W, John Parrott N, Zhang J, Schmucki R, Racek T, Hoflack J, Kueng E, Point F, Zhou X, Steiner G, Lütgehetmann M, Rapp G, Volz T, Dandri M, Yang S, Young J, Javanbakht H
J HEPATOL. 2018;68(3):412-420.

2017

The Role of cccDNA in HBV Maintenance
Allweiss L, Dandri M
VIRUSES-BASEL. 2017;9(6):.

Immunofluorescent Staining for the Detection of the Hepatitis B Core Antigen in Frozen Liver Sections of Human Liver Chimeric Mice
Allweiss L, Lütgehetmann M, Dandri M
Methods Mol Biol. 2017;1540:135-142.

Animal models of HBV infection
Dandri M, Petersen J
BEST PRACT RES CL GA. 2017;31(3):273-279.

Serum HBV pgRNA as a clinical marker for cccDNA activity
Giersch K, Allweiss L, Volz T, Dandri-Petersen M, Lütgehetmann M
J HEPATOL. 2017;66(2):460-462.

Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV/HDV infected humanized mice
Giersch K, Homs M, Volz T, Helbig M, Allweiss L, Lohse A, Petersen J, Buti M, Pollicino T, Sureau C, Dandri M, Lütgehetmann M
SCI REP-UK. 2017;7(1):3757.

Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection
Kah J, Koh S, Volz T, Ceccarello E, Allweiss L, Lütgehetmann M, Bertoletti A, Dandri M
J CLIN INVEST. 2017;127(8):3177-3188.

Heme oxygenase-1 polymorphisms can affect HCV replication and treatment responses with different efficacy in humanized mice
Kah J, Volz T, Lütgehetmann M, Groth A, Lohse A, Tiegs G, Sass G, Dandri-Petersen M
LIVER INT. 2017;37(8):1128-1137.

Multi-color RGB marking enables clonality assessment of liver tumors in a murine xenograft model
Thomaschewski M, Riecken K, Unrau L, Volz T, Cornils K, Ittrich H, Heim D, Wege H, Akgün E, Lütgehetmann M, Dieckhoff J, Köpke M, Dandri M, Benten D, Fehse B
ONCOTARGET. 2017;8(70):115582-115595.

Cold-induced conversion of cholesterol to bile acids in mice shapes the gut microbiome and promotes adaptive thermogenesis
Worthmann A, John C, Rühlemann M, Baguhl M, Heinsen F, Schaltenberg N, Heine M, Schlein C, Evangelakos I, Mineo C, Fischer M, Dandri M, Kremoser C, Scheja L, Franke A, Shaul P, Heeren J
NAT MED. 2017;23(7):839-849.

2016

Experimental in vitro and in vivo models for the study of human hepatitis B virus infection
Allweiss L, Dandri-Petersen M
J HEPATOL. 2016;64(1 Suppl):S17-31.

Human liver chimeric mice as a new model of chronic hepatitis E virus infection and preclinical drug evaluation
Allweiss L, Gass S, Giersch K, Groth A, Kah J, Volz T, Rapp G, Schöbel A, Lohse A, Polywka S, Pischke S, Herker E, Dandri-Petersen M, Lütgehetmann M
J HEPATOL. 2016;64(5):1033-1040.

Primary Human Hepatocytes Repopulate Livers of Mice After In Vitro Culturing and Lentiviral-Mediated Gene Transfer
Bierwolf J, Volz T, Lütgehetmann M, Allweiss L, Riecken K, Warlich M, Fehse B, Kalff J, Dandri-Petersen M, Pollok J
TISSUE ENG PT A. 2016;22(9-10):742-53.

The challenge of protecting without overprotecting the two sides of myeloid-derived suppressor cells in HBV infection
Dandri-Petersen M, Bockmann J
HEPATOLOGY. 2016;63(3):1044-6.

Latest developments in the treatment of hepatitis B
Dandri-Petersen M, Petersen J
Minerva Gastroenterol Dietol. 2016;62(1):88-102.

Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential
Dandri-Petersen M, Petersen J
CLIN INFECT DIS. 2016;62 Suppl 4:S281-8.

Variability in long-term hepatitis B virus dynamics under antiviral therapy
Murray J, Stancevic O, Lütgehetmann M, Wursthorn K, Petersen J, Dandri-Petersen M
J THEOR BIOL. 2016;391:74-80.

A Slow Maturation Process Renders Hepatitis B Virus Infectious
Seitz S, Iancu C, Volz T, Mier W, Dandri-Petersen M, Urban S, Bartenschlager R
CELL HOST MICROBE. 2016;20(1):25-35.

2015

Combined glucocorticoid and antiviral therapy of hepatitis B virus-related liver failure
Bockmann J, Dandri-Petersen M, Lüth S, Pannicke N, Lohse A, Dandri-Petersen M
WORLD J GASTROENTERO. 2015;21(7):2214-9.

Experimental Models: Cell Culture and Animal Models
Dandri-Petersen M, Volz T, Lütgehetmann M
2015. Hepatitis B Virus in Human Diseases . Liaw Y, Zoulim F (Hrsg.). 1. Aufl. Springer International Publishing, 35-62.

Hepatitis Delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBV mono-infection
Giersch K, Allweiss L, Volz T, Helbig M, Bierwolf J, Lohse A, Pollok J, Petersen J, Dandri-Petersen M, Lütgehetmann M
J HEPATOL. 2015;63(2):346-53.

Hepatitis B and Delta Virus: Advances on Studies about Interactions between the Two Viruses and the Infected Hepatocyte
Giersch K, Dandri-Petersen M
J CLIN TRANSL HEPATO. 2015;3(3):220-229.

Comparison of autochthonous and imported cases of hepatitis A or hepatitis E
Hartl J, Kreuels B, Polywka S, Addo M, Lütgehetmann M, Dandri-Petersen M, Dammermann W, Sterneck M, Lohse A, Pischke S
Z GASTROENTEROL. 2015;53(7):639-643.

Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody
Mailly L, Xiao F, Lupberger J, Wilson G, Aubert P, Duong F, Calabrese D, Leboeuf C, Fofana I, Thumann C, Bandiera S, Lütgehetmann M, Volz T, Davis C, Harris H, Mee C, Girardi E, Chane-Woon-Ming B, Ericsson M, Fletcher N, Bartenschlager R, Pessaux P, Vercauteren K, Meuleman P, Villa P, Kaderali L, Pfeffer S, Heim M, Neunlist M, Zeisel M, Dandri-Petersen M, McKeating J, Robinet E, Baumert T
NAT BIOTECHNOL. 2015;33(5):549-54.

Optimal therapy for chronic hepatitis B: hepatitis B virus combination therapy?
Petersen J, Dandri-Petersen M
LIVER INT. 2015;35 Suppl 1:114-20.

2014

Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration
Allweiss L, Volz T, Lütgehetmann M, Giersch K, Bornscheuer T, Lohse A, Petersen J, Ma H, Klumpp K, Fletcher S, Dandri M
J HEPATOL. 2014;60(3):500-7.

Multiplexing clonality: combining RGB marking and genetic barcoding
Cornils K, Thielecke L, Hüser S, Forgber M, Thomaschewski M, Kleist N, Hussein K, Riecken K, Volz T, Gerdes S, Glauche I, Dahl A, Dandri M, Roeder I, Fehse B
NUCLEIC ACIDS RES. 2014;42(7):e56.

Mouse models of hepatitis B and delta virus infection
Dandri M, Lütgehetmann M
J IMMUNOL METHODS. 2014;410:39-49.

Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection
Giersch K, Helbig M, Volz T, Allweiss L, Mancke L, Lohse A, Polywka S, Pollok J, Petersen J, Taylor J, Dandri M, Lütgehetmann M
J HEPATOL. 2014;60(3):538-44.

Relevance of a Full-Length Genomic RNA Standard and a Thermal-Shock Step for Optimal Hepatitis Delta Virus Quantification
Homs M, Giersch K, Blasi M, Lütgehetmann M, Buti M, Esteban R, Dandri M, Rodriguez-Frias F
J CLIN MICROBIOL. 2014;52(9):3334-8.

Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA
Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl M, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou W, Thasler W, Hüser N, Durantel D, Liang T, Münk C, Heim M, Browning J, Dejardin E, Dandri M, Schindler M, Heikenwalder M, Protzer U
SCIENCE. 2014;343(6176):1221-1228.

Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism
Oehler N, Volz T, Bhadra O, Kah J, Allweiss L, Giersch K, Bierwolf J, Riecken K, Pollok J, Lohse A, Fehse B, Petersen J, Urban S, Lütgehetmann M, Heeren J, Dandri M
HEPATOLOGY. 2014.

Matrix Conditions and KLF2-Dependent Induction of Heme Oxygenase-1 Modulate Inhibition of HCV Replication by Fluvastatin
Wüstenberg A, Kah J, Singethan K, Sirma H, Keller A, Perez Rosal S, Schrader J, Loscher C, Volz T, Bartenschlager R, Lohmann V, Protzer U, Dandri M, Lohse A, Tiegs G, Sass G
PLOS ONE. 2014;9(5):e96533.

2013

Experimental models and therapeutic approaches for HBV
Dandri M, Lütgehetmann M, Petersen J
SEMIN IMMUNOPATHOL. 2013;35(1):7-21.

Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B?
Thimme R, Dandri M
J HEPATOL. 2013;58(2):205-209.

The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus
Volz T, Allweiss L, Ben MBarek M, Warlich M, Lohse A, Pollok J, Alexandrov A, Urban S, Petersen J, Lütgehetmann M, Dandri M
J HEPATOL. 2013;58(5):861-7.

2012

IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome.
Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, Petersen J, Raimondo G, Dandri-Petersen M, Levrero M
J CLIN INVEST. 2012;122(2):529-537.

Primary human hepatocytes from metabolic-disordered children recreate highly differentiated liver-tissue-like spheroids on alginate scaffolds.
Bierwolf J, Lütgehetmann M, Deichmann S, Erbes J, Volz T, Dandri-Petersen M, Cohen S, Nashan B, Pollok J
TISSUE ENG PT A. 2012;18(13-14):1443-1453.

Chimeric mouse model of hepatitis B virus infection.
Dandri M, Petersen J
J HEPATOL. 2012;56(2):493-495.

New insight in the pathobiology of hepatitis B virus infection.
Dandri-Petersen M, Locarnini S
GUT. 2012;61 Suppl 1:6-17.

Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression.
Kah J, Wüstenberg A, Keller A, Sirma H, Montalbano R, Ocker M, Volz T, Dandri-Petersen M, Tiegs G, Sass G
ONCOL REP. 2012;28(3):1077-1083.

Induction of heme oxygenase 1 by HMG-CoA-Reductase inhibitors interferes with HCV replication
Loscher C, Wüstenberg A, Keller A, Lehmann E, Sirma H, Bartenschlager R, Lohmann V, Dandri-Petersen M, Tiegs G, Sass G
2012. Zeitschrift für Gastroenterologie. .

Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.
Lütgehetmann M, Mancke L, Volz T, Helbig M, Allweiss L, Bornscheuer T, Pollok J, Lohse A, Petersen J, Urban S, Dandri-Petersen M
HEPATOLOGY. 2012;55(3):685-694.

Strong antiviral activity of the new l-hydroxycytidine derivative, l-Hyd4FC, in HBV-infected human chimeric uPA/SCID mice.
Volz T, Lütgehetmann M, Allweiss L, Warlich M, Bierwolf J, Pollok J, Petersen J, Matthes E, Dandri-Petersen M
ANTIVIR THER. 2012;17(4):623-631.

2011

Hepatitis B virus limits response of human hepatocytes to interferon-α in chimeric mice.
Lütgehetmann M, Bornscheuer T, Volz T, Allweiss L, Bockmann J, Pollok J, Lohse A, Petersen J, Dandri-Petersen M
GASTROENTEROLOGY. 2011;140(7):1-2, 2074-2083.

RGB marking facilitates multicolor clonal cell tracking.
Riecken K, Thomaschewski M, Warlich M, Volz T, Cornils K, Niebuhr B, Täger M, Lütgehetmann M, Pollok J, Stocking C, Dandri-Petersen M, Benten D, Fehse B
NAT MED. 2011;17(4):504-509.

2010

Mobilization of hematopoietic progenitor cells in patients with liver cirrhosis.
Gehling U, Willems M, Schlagner K, Benndorf R, Dandri-Petersen M, Petersen J, Sterneck M, Pollok J, Hossfeld D, Rogiers X
WORLD J GASTROENTERO. 2010;16(2):217-224.

Wissensstand, Präventionsverhalten und Therapieadhärenz von Patienten mit chronischer Hepatitis B in einem großen tertiären Zentrum in Deutschland
Lutgehetmann M, Meyer F, Volz T, Lohse A, Fischer C, Dandri M, Petersen J
Z GASTROENTEROL. 2010;48(9):1126-32.

[Knowledge about HBV, prevention behaviour and treatment adherence of patients with chronic hepatitis B in a large referral centre in Germany].
Lütgehetmann M, Meyer F, Volz T, Lohse A, Fischer C, Dandri-Petersen M, Petersen J
Z GASTROENTEROL. 2010;48(9):1126-1132.

In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice.
Lütgehetmann M, Volz T, Köpke A, Broja T, Tigges E, Lohse A, Fuchs E, Murray J, Petersen J, Dandri-Petersen M
HEPATOLOGY. 2010;52(1):16-24.

2009

Control of cccDNA function in hepatitis B virus infection.
Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri-Petersen M
J HEPATOL. 2009;51(3):581-592.

The replication cycle of hepatitis B virus.
Urban S, Schulze A, Dandri-Petersen M, Petersen J
J HEPATOL. 2009.

2008

Virion half-life in chronic hepatitis B infection is strongly correlated with levels of viremia.
Dandri-Petersen M, Murray J, Lütgehetmann M, Volz T, Lohse A, Petersen J
HEPATOLOGY. 2008;48(4):1079-1086.

Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication.
Lütgehetmann M, Volz T, Quaas A, Zankel M, Fischer C, Dandri-Petersen M, Petersen J
ANTIVIR THER. 2008;13(1):57-66.

Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.
Petersen J, Dandri-Petersen M, Mier W, Lütgehetmann M, Volz T, von Weizsäcker F, Haberkorn U, Fischer L, Pollok J, Erbes B, Seitz S, Urban S
NAT BIOTECHNOL. 2008;26(3):335-341.

2007

Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients.
Volz T, Lütgehetmann M, Wachtler P, Jacob A, Quaas A, Murray J, Dandri-Petersen M, Petersen J
GASTROENTEROLOGY. 2007;133(3):843-852.

2006

Small animal model systems for studying hepatitis B virus replication and pathogenesis.
Dandri-Petersen M, Lütgehetmann M, Volz T, Petersen J
SEMIN LIVER DIS. 2006;26(2):181-191.

Morphological and functional analysis of rat hepatocyte spheroids generated on poly(L-lactic acid) polymer in a pulsatile flow bioreactor.
Török E, Vogel C, Lütgehetmann M, Ma P, Dandri-Petersen M, Petersen J, Burda M, Siebert K, Düllmann J, Rogiers X, Pollok J
TISSUE ENG. 2006;12(7):1881-1890.

Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.
Wursthorn K, Lütgehetmann M, Dandri-Petersen M, Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M, Fischer C, Currie G, Brosgart C, Petersen J
HEPATOLOGY. 2006;44(3):675-684.

2005

Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes.
Dandri-Petersen M, Burda M, Zuckerman D, Wursthorn K, Matschl U, Pollok J, Rogiers X, Gocht A, Köck J, Blum H, von Weizsäcker F, Petersen J
J HEPATOL. 2005;42(1):54-60.

Hepatitis B virus cccDNA clearance: killing for curing?
Dandri-Petersen M, Petersen J
HEPATOLOGY. 2005;42(6):1453-1455.

Animal models for the study of HBV replication and its variants.
Dandri-Petersen M, Volz T, Lütgehetmann M, Petersen J
J CLIN VIROL. 2005;34(1):54-62.

Partial hepatectomy induces mobilization of a unique population of haematopoietic progenitor cells in human healthy liver donors.
Gehling U, Willems M, Dandri-Petersen M, Petersen J, Berna M, Thill M, Wulf T, Müller L, Pollok J, Schlagner K, Faltz C, Hossfeld D, Rogiers X
J HEPATOL. 2005;43(5):845-853.

2004

Transplantation of human hepatocytes in immunodeficient UPA mice: a model for the study of hepatitis B virus.
Petersen J, Burda M, Dandri-Petersen M, Rogler C
Methods Mol Med. 2004;96:253-260.

2003

Quantitative gene expression analysis reveals transition of fetal liver progenitor cells to mature hepatocytes after transplantation in uPA/RAG-2 mice.
Cantz T, Zuckerman D, Burda M, Dandri-Petersen M, Göricke B, Thalhammer S, Heckl W, Manns M, Petersen J, Ott M
AM J PATHOL. 2003;162(1):37-45.

2002

Increase in de novo HBV DNA integrations in response to oxidative DNA damage or inhibition of poly(ADP-ribosyl)ation.
Dandri-Petersen M, Burda M, Bürkle A, Zuckerman D, Will H, Rogler C, Greten H, Petersen J
HEPATOLOGY. 2002;35(1):217-223.

2001

Structural and functional heterogeneity of naturally occurring hepatitis B virus variants.
Burda M, Günther S, Dandri-Petersen M, Will H, Petersen J
ANTIVIR RES. 2001;52(2):125-138.

Woodchuck hepatocytes remain permissive for hepadnavirus infection and mouse liver repopulation after cryopreservation.
Dandri-Petersen M, Burda M, Gocht A, Török E, Pollok J, Rogler C, Will H, Petersen J
HEPATOLOGY. 2001;34(4 Pt 1):824-833.

Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus.
Dandri-Petersen M, Burda M, Török E, Pollok J, Iwanska A, Sommer G, Rogiers X, Rogler C, Gupta S, Will H, Greten H, Petersen J
HEPATOLOGY. 2001;33(4):981-988.

Optimization of hepatocyte spheroid formation for hepatic tissue engineering on three-dimensional biodegradable polymer within a flow bioreactor prior to implantation.
Török E, Pollok J, Ma P, Kaufmann P, Dandri-Petersen M, Petersen J, Burda M, Kluth D, Perner F, Rogiers X
CELLS TISSUES ORGANS. 2001;169(1):34-41.

Hepatic tissue engineering on 3-dimensional biodegradable polymers within a pulsatile flow bioreactor.
Török E, Pollok J, Ma P, Vogel C, Dandri-Petersen M, Petersen J, Burda M, Kaufmann P, Kluth D, Rogiers X
DIGEST SURG. 2001;18(3):196-203.

2000

Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA.
Dandri-Petersen M, Burda M, Will H, Petersen J
HEPATOLOGY. 2000;32(1):139-146.

1998

Metabolic labeling of woodchuck hepatitis B virus X protein in naturally infected hepatocytes reveals a bimodal half-life and association with the nuclear framework.
Dandri-Petersen M, Petersen J, Stockert R, Harris T, Rogler C
J VIROL. 1998;72(11):9359-9364.

Liver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma.
Petersen J, Dandri-Petersen M, Gupta S, Rogler C
P NATL ACAD SCI USA. 1998;95(1):310-315.

Antisense downregulation of N-myc1 in woodchuck hepatoma cells reverses the malignant phenotype.
Wang H, Zhang L, Dandri-Petersen M, Rogler C
J VIROL. 1998;72(3):2192-2198.

1997

Increase in the frequency of hepadnavirus DNA integrations by oxidative DNA damage and inhibition of DNA repair.
Petersen J, Dandri-Petersen M, Bürkle A, Zhang L, Rogler C
J VIROL. 1997;71(7):5455-5463.

1996

Woodchuck hepatitis virus X protein is present in chronically infected woodchuck liver and woodchuck hepatocellular carcinomas which are permissive for viral replication.
Dandri-Petersen M, Schirmacher P, Rogler C
J VIROL. 1996;70(8):5246-5254.

1993

Trans-activation of epidermal growth factor receptor gene by the hepatitis B virus X-gene product.
Menzo S, Clementi M, Alfani E, Bagnarelli P, Iacovacci S, Manzin A, Dandri-Petersen M, Natoli G, Levrero M, Carloni G
VIROLOGY. 1993;196(2):878-882.

Letzte Aktualisierung aus dem FIS: 14.05.2025 - 10:59 Uhr